Methyclothiazide
FDA-approved product (tablet, oral), marketed as Aquatensen, Enduron, Methyclothiazide.
- Registered studies
- 5
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cardiovascular disease
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Thiazides, plain
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA34.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli35.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae17.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis64.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
5registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Methyclothiazide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Dolutegravir SodiumExisting use: HIV infection, HIV-1 infection55.9% AI-predicted activityagainst E. coli50+ registered studies
- Desmopressin AcetateExisting use: Central diabetes insipidus, Diabetes insipidus, Enuresis and 5 more55.8% AI-predicted activityagainst E. coli50+ registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia55.8% AI-predicted activityagainst E. coli50+ registered studies
- Cetrorelix AcetateExisting use: Ovulation Inhibition, Positive regulation of ovulation55.7% AI-predicted activityagainst E. coli50+ registered studies
- Setmelanotide AcetateExisting use: Obesity55.6% AI-predicted activityagainst E. coliNo documented evidence found
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more55.6% AI-predicted activityagainst E. coli50+ registered studies
- LurbinectedinExisting use: Cancer, Neoplasm, Small cell lung carcinoma55.4% AI-predicted activityagainst E. coli50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted55.4% AI-predicted activityagainst E. coli50+ registered studies
- Icatibant AcetateExisting use: Angioedema, Hereditary angioedema55.2% AI-predicted activityagainst E. coli33 registered studies
- Dihydroergotamine MesylateExisting use: Migraine disorder55.2% AI-predicted activityagainst E. coli21 registered studies
- Triptorelin PamoateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 3 more55.2% AI-predicted activityagainst E. coli50+ registered studies
- LypressinExisting use: Vasopressin and analogues55.1% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Analysis of Crosslinked and Conventional Polyethylene Explants
NCT01484002 · start 2011-12
Registered record
- Registry ID
- NCT01484002
- Conditions
- Osteoarthritis
- Interventions
- Total hip arthroplasty
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2011-12
- Completion
- 2017-12
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteoarthritisInterventionTotal hip arthroplastyPhaseNot recordedRegistry statusUnknownA Multi-centre Study to Assess the Long-term Performance of the Pinnacle™ Cup With a Polyethylene-on-metal Bearing in Primary Total Hip Replacement
NCT00208429 · start 2004-07-01
Registered record
- Registry ID
- NCT00208429
- Conditions
- Rheumatoid Arthritis; Osteoarthritis; Post-traumatic Arthritis; Collagen Disorders; Avascular Necrosis; Traumatic Femoral Fractures; Nonunion of Femoral Fractures; Congenital Hip Dysplasia; Slipped Capital Femoral Epiphysis
- Interventions
- Pinnacle Acetabular System
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Withdrawn
- Start
- 2004-07-01
- Completion
- 2019-07-01
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRheumatoid Arthritis; Osteoarthritis; Post-traumatic Arthritis; Collagen Disorders +5 moreInterventionPinnacle Acetabular SystemPhasePhase 4Registry statusWithdrawnA Randomised Single Centre Study to Compare the Long-term Wear Characteristics of Marathon™ and Enduron™ Polyethylene Cup Liners in Primary Total Hip Replacement
NCT00208442 · start 2001-06-01
Registered record
- Registry ID
- NCT00208442
- Conditions
- Osteoarthritis; Post-traumatic Arthritis; Collagen Disorders; Avascular Necrosis; Traumatic Femoral Fractures; Nonunion of Femoral Fractures; Congenital Hip Dysplasia; Slipped Capital Femoral Epiphysis
- Interventions
- Marathon™; Enduron
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2001-06-01
- Completion
- 2013-09-01
- Enrolment
- 122
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteoarthritis; Post-traumatic Arthritis; Collagen Disorders; Avascular Necrosis +4 moreInterventionMarathon™; EnduronPhasePhase 4Registry statusCompletedMarathon and Enduron Polyethylene at Long-Term Follow-up
NCT02508428 · start 1999-01-06
Registered record
- Registry ID
- NCT02508428
- Conditions
- Osteoarthritis; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases
- Interventions
- Hip Replacement with crosslinked Marathon polyethylene; Hip Replacement with noncrosslinked Enduron polyethylene
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 1999-01-06
- Completion
- 2017-06-22
- Enrolment
- 230
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteoarthritis; Arthritis; Joint Diseases; Musculoskeletal Diseases +1 moreInterventionHip Replacement with crosslinked Marathon polyethylene; Hip Replacement with noncrosslinked Enduron polyethylenePhaseNot applicableRegistry statusCompletedStudy Comparing Marathon Polyethylene and Enduron Polyethylene Acetabular Liners Used in Total Hip Arthroplasty
NCT01121146 · start 1998-12
Registered record
- Registry ID
- NCT01121146
- Conditions
- Osteoarthritis; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases
- Interventions
- Total Hip Replacement
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 1998-12
- Completion
- 2012-03
- Enrolment
- 236
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteoarthritis; Arthritis; Joint Diseases; Musculoskeletal Diseases +1 moreInterventionTotal Hip ReplacementPhaseNot applicableRegistry statusCompleted